FILTER
FILTERED INTERVIEW RESULTS
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Doug Giordano
SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.
Michael Gladstone
PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.
David DeJean
SENIOR VICE PRESIDENT, SYSTECH INTERNATIONAL
Systech International is a technology leader in supply chain safety and brand protection.
Robert Foster
CEO, HEPION PHARMACEUTICALS
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease.
Daniel J O’Connor
PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using its plasmid DNA delivery platform.
Peter Meath
MANAGING DIRECTOR & CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, J.P. MORGAN COMMERCIAL BANKING
.P.Morgan explains the complete ecosystem that it has developed for life science companies, aiming to serve their needs throughout their entire life cycle, from opening a bank account on Day 1, to expanding internationally and through a potential IPO and beyond.
John Patrick Oroho
EXECUTIVE VICE PRESIDENT AND CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES, LLC
Porzio Life Sciences, LLC (PorzioLS) is a provider of compliance operations products and services for the life sciences industry, and a wholly‐owned subsidiary of the Porzio, Bromberg & Newman, P.C. law firm.
Ciara Kennedy
PRESIDENT AND CEO, AMPLYX PHARMACEUTICALS
Amplyx Pharmaceuticals has a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients.
Nataliya Katsnelson
DIRECTOR – BUSINESS DEVELOPMENT, GLOBAL CLINICAL TRIALS
GCT is a CRO providing clinical development services for drugs and medical devices, with operations focused on Central and Eastern Europe, Russia and India.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
